Zydus Lifesciences Ltd. | Success Story of India's 4th biggest pharma co.

Shalini Rath Shalini Rath
Oct 11, 2022 10 min read
Zydus Lifesciences Ltd. | Success Story of India's 4th biggest pharma co.

Company Profile is an initiative by StartupTalky to publish verified information on different startups and organizations. The content in this post has been approved by Cadila Healthcare Limited.

To begin, the pharmaceutical industry has shown immense growth over the years. Every pharma product goes through a series of stringent research, innovation, and regulation to deliver good quality drugs and medicines, after all, it is a matter of health.

One cannot even imagine a life without medicines and drugs. Today, we have so many medicines for flu and fever and other key discoveries related to prolonged illnesses as well.

Previously known as Cadila Healthcare Limited, Zydus Lifesciences Limited, an Indian multinational pharma company is primarily engaged in the manufacture of generic drugs. Founded in 1952 by Ramanbhai Patel, Zydus Lifesciences Limited has its corporate office in Ahmedabad (Gujarat), India.


Zydus Lifesciences Limited - Company Highlights

Headquarters Ahmedabad, India
Sector Pharmaceuticals
Type Public
Founder Ramanbhai Patel
Founded 1952
Valuation Rs 37,991.09 crores
Revenue Rs 15,139 crores (FY2021)
Total Funding Raised $7 million
Website www.zyduslife.com

Zydus Lifesciences Limited - About
Zydus Lifesciences Limited - Industry Details
Zydus Lifesciences Limited - Founder and Team
Zydus Lifesciences Limited - Startup Story
Zydus Lifesciences Limited - Mission and Vision
Zydus Lifesciences Limited - Name, Tagline, Logo
Zydus Lifesciences Limited - Business Model
Zydus Lifesciences Limited - Revenue Model
Zydus Lifesciences Limited - Funding and Investors
Zydus Lifesciences Limited - Mergers and Acquisitions
Zydus Lifesciences Limited - Advertisements and Social Media Campaigns
Zydus Lifesciences Limited - Awards and Achievements
Zydus Lifesciences Limited - Competitors
Zydus Lifesciences Limited - Future Plans
FAQs

Zydus Lifesciences Limited - About

Zydus Lifesciences is thoroughly engaged in producing formulations for active pharmaceutical ingredients, animal healthcare products, and wellness products. Furthermore, it creates and produces a wide variety of medications, diagnostics, herbal remedies, cosmetics items, and other over-the-counter (OTC) goods.

It is a leading Indian pharmaceutical business and a fully integrated, international healthcare provider. It has excellent capabilities across the whole pharmaceutical value chain and extensive domain understanding in the field of healthcare.

Zydus Lifesciences has its headquarters in Ahmedabad, India. It has the fourth-place position in the country's pharmaceutical market, with production and research facilities dispersed over five states: Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim. Globally, the group is well-represented in the highly visible markets of Latin America and South Africa as well as the regulated markets of the US and Europe (France and Spain). It is also well-established in 25 other developing markets throughout the world.

Zydus is a pharmaceutical business focused on research, along with 1300 researchers operating across 19 facilities on its innovation program, which is developing distinctive medications for the future. NCEs, vaccines, biosimilars, and specialized technologies are just a few of the ideas and concepts the group is studying while also constantly inventing.

Zydus Lifesciences has four major subsidiaries, these are:

  • Zydus Wellness Limited (ZWL) - The company re-launched the Complan  brand with improved taste and packaging design
  • Lipaglyn Saroglitazar - A new drug in treating Diabetic Dyslipidemia
  • Exemptia Adalimumab -  It is an anti-inflammatory drug
  • ZyCoV-D - The Drugs Controller General of India (DCGI), Government of India, granted the company authorization to undertake human trials of the developing COVID-19 vaccine dubbed ZyCoV-D in 2020.

Zydus Lifesciences' CSR & EHS initiatives

The company's aims and business operations include a commitment to environmental conservation, employee health, and safety. It has a dedicated Environment, Health, and Safety (EHS) cell that works with all stakeholders across functions to create a distinct EHS culture to achieve environmental, health, and safety excellence across all units.

Zydus Shrishti, the company's CSR initiative, focuses on health, education, and research. The Zydus Foundation has established the Zydus Medical College and Hospital in Dahod. The hospital provides free care for patients, including OPD, hospitalization, all investigations, operations, anesthesia, oral drugs, injectables, and meals.

It has also set up a medical college in Dahod, which is a self-financed brownfield medical college project established under the Government of Gujarat's Public Private Partnership (PPP) model.

Zydus has conducted over 3000 awareness sessions on the prevention of various disease conditions.

Zydus Lifesciences Limited - Industry Details


The pharmaceutical business is massive, with a global market of more than US$ 1.4 trillion. Moreover, COVID-19 increased worldwide drug consumption, owing to fast immunization and the development of novel treatment options. Global COVID-19 investment is estimated to approach $80 billion in 2021, with total spending exceeding $251 billion through 2026.

Nevertheless, India is a prominent and expanding player in the global medicines market. It is no surprise that India is the world's largest provider of generic pharmaceuticals, accounting for 20% of global supply by volume and fulfilling over 60% of global immunization demand.

Zydus Lifesciences Limited - Founder and Team

Zydus Lifesciences Limited was founded by Indian chemist, Ramanbhai B. Patel in 1952.

Ramanbhai B. Patel

Ramanbhai Patel was born in South Gujarat in Kathor on 19 August 1925. Before working as an instructor there, he was a student of chemistry at Gujarat University's L.M. College of Pharmacy. He founded Cadila Laboratories with his school friend Indravadan Modi in 1951. However, due to some disagreements, the business split in two in 1995; Raman Patel established Cadila Healthcare, and Modi established Cadila Pharmaceuticals. The 2019 Gandhi Mandela Peace Award was hosted by Ramanbhai Patel. Ramanbhai Patel passed away on 19 September 2001 in Mumbai, India.

Pankaj R. Patel

Pankaj Ramanbhai Patel is a multimillionaire businessman. He was born in 1953 and is the Chairman of Cadila Healthcare, now known as Zydus Lifesciences. He has a Bachelor of Arts in Science and Law from the University of Mumbai, and a Bachelor of Pharmacy and Master of Pharmacy degrees from Gujarat University. Pankaj Patel joined Cadila Healthcare, which was established by his father, Ramanbhai Patel in 1952 to produce vitamins, after receiving his degree.

Pankaj Patel serves as the chairman of the boards of governors of the Indian Institute of Science Education and Research in Kolkata and the Indian Institute of Technology in Bhubaneswar. He is also a member of the boards of governors and the chairman of the finance committee of the Indian Institute of Management in Ahmedabad, the chairman of IIM Udaipur, the chairman of the school of life sciences at Ahmedabad University, and the board of management of the Ahmedabad University.

In honor of the expansion of Cadila under his direction, Pankaj Patel was named the "Best Pharma Man of the Year of 2003" by the Foundation of Indian Industry and Economists. Pankaj Patel is married to Priti Patel and has two children.

Zydus Lifesciences Limited - Startup Story

The story begins when Ramanbhai Patel and his business partner Indravadan Modi established Cadila in 1952. Over the subsequent forty years, it developed into a well-known pharmaceutical corporation.

In those years, Isopar, a combination of the anti-tuberculosis medications isoniazid and para-aminosalicylic acid, was produced in 1957, and Neuroxin-12, a single-vial mixture of vitamins B1, B6, and B12, was produced in 1959.

Things got changed when the Modi and Patel families separated in 1995.  The Modi family's portion was transferred to a new business called Cadila Pharmaceuticals Ltd., while Cadila Healthcare Ltd. became the holding company for the Patel family. In 2000, Cadila Healthcare under the stock number 532321 had its first public offering on the Bombay Stock Exchange.

Under the trade name Exemptia, Zydus Lifesciences introduced the first adalimumab biosimilar in 2014 at a price that was one-fifth that of the original. Saroglitazar, a medicine based on research, has also been made available by the company under the trade name "Lipaglyn" for the treatment of diabetic dyslipidemia. Zydus introduced SoviHep, the first sofosbuvir brand, to India in 2015.

2019 saw the recall of injectable ketorolac tromethamine produced by Zydus (Cadila Healthcare) owing to microbial development.

Zydus Lifesciences Limited replaces Cadila Healthcare Limited as the company name in 2022.

Zydus Lifesciences Limited - Mission and Vision

The mission statement of Zydus is, "To unlock new possibilities in life sciences through quality healthcare solutions that impact lives."

Zydus's vision reads, "To be a global life sciences company transforming lives through pathbreaking discoveries."

The company aims to give people the independence they need to lead healthier, and more contented lives.

Before Zydus Lifesciences, the company was popularly known as Cadila Healthcare Limited. The tagline of Zydus Lifesciences is, "Dedicated to Life"

Its new logo depicts a stylized representation of two hearts with the word "Us" in the middle. Zydus's logo colors are vivid and deeply symbolic highlighting the fact that everything the company does is for them which is "Us", which includes the company's diverse group of stakeholders, including staff members, patients, carers, partners, and customers.

The teal color in the logo expresses the company's dynamism and purple symbolizes its purposefulness and dedication.

Zydus Lifesciences Limited - Business Model

As mentioned earlier, Zydus is mainly involved in the manufacturing of generic drugs, APIs, Animal healthcare products, and other OTC goods. The company has a global manufacturing footprint of 35 facilities that adhere to strong regulatory compliance requirements and have the capacity to manufacture multiple dosage forms at scale, allowing it to provide clients globally with cost-effective and high-quality pharmaceutical goods. About 7-8% of its annual revenues are invested in research and development.

Here's taking a look at Zydus's main business operations:

  • Zydus Research Centre (ZRC) is the company's specialized unit in charge of driving its NCE research efforts. Cardiometabolic illnesses, inflammation, fibrosis, and infectious diseases are among ZRC's NCE research priorities.
  • The Company's vaccine development projects are housed in the Vaccines Technology Centre (VTC) in Ahmedabad. VTC has been working on vaccines for basic vaccination programs such as Diphtheria, Pertussis, Tetanus, Haemophilus Influenzae type B, Hepatitis B, Measles, Mumps, Rubella, Varicella, Influenza, and Typhoid fever, as well as new vaccines such as Human Papilloma Virus, Leishmaniasis, Malaria, Haemorrhagic Congo Fever, Ebola, and Japanese Encephalitis.
  • Specialty and Complex Generics. The Company's Specialty portfolio is focused on offering value-added therapies that meet unmet requirements while also providing patients and providers with a viable economic opportunity.
  • The company has one of the most complete and diversified biological product portfolios. The portfolio includes therapeutic fields like oncology, autoimmune illness, nephrology, ophthalmology, and other fields, including rheumatology, inflammation, hepatology, infectious illness, etc.
  • The group's generic pharmaceutical development R&D operations are carried out in three Pharmaceutical Technology Centres (PTC) in Ahmedabad, India. These Centers provide formulations for worldwide markets, with a focus on specialty dosage forms and the development of skills on multiple technological platforms.

Zydus's India Business

The company's domestic's business is divided into three major business segments; specialty business, chronic business, and mass business. It was the fastest growing company in India in the oncology sector while maintaining a leadership position in the super specialty of nephrology. To prevent and treat a variety of diseases in the fields of oncology, hepatology, nephrology, rheumatology, ophthalmology, and bone health, Zydus Biologics, a super-specialty centric business entity of Zydus Lifesciences Ltd., manufactures and commercializes both small molecule, biological drugs, and vaccines. It has launched around 37 new products including line extensions, out of which 13 were first in the domestic market.

Domestic sales increased by 7% to Rs 19,788 million, with a 160% increase in net profit to Rs 3,089 million. (FY2021-2022)

Zydus's USA Business

Zydus Lifesciences has been ranked 5th among US generic companies based on prescriptions. The company's business involved the launch of  14 products during 2021-2022. Despite growing competition and pricing pressure, the company tends to gain total volume and maintained a top three ranking in around 60% of product families. In terms of volume, the company led in around 20% of the product groups. Sales made in the USA were reported to be Rs 58,138 million.

Zydus's Asia, Africa, and Latin America Business

With 30 products classified as leaders in their respective molecular categories, the company reclaimed first place in Sri Lanka with a 7.4% market share. Zydus's international business sales increased by 17% to Rs 11,921 million.

Zydus Lifesciences Limited - Revenue Model

The total revenue made by Zydus Lifesciences is reported to be Rs 15,139 crores. It claims that its total income from operations grew by 6% to Rs 152.7 crores from Rs 144 crores last year (2020-2021). There was a 21% Y-o-Y increase in the branded business (excluding sales of COVID-related products, the generics portfolio, and sold brands). Twelve of the company's products are among India's top 300 pharmaceutical brands. During 2021-2022, eight brands had sales above Rs 100 crores, 22 brands had sales between Rs 50 and Rs 100 crores, and 36 brands had sales between Rs 25 and Rs 50 crores.

Zydus Lifesciences Limited - Funding and Investors

Zydus Lifesciences Ltd. has three joint ventures. Some of these are;

  • Zydus Takeda Healthcare Pvt. Ltd. - It is a 50:50 joint venture between the Company and Takeda Pharmaceuticals Co. Ltd., (Japan)
  • Zydus Hospira Oncology Pvt. Ltd - It is a 50:50 contract manufacturing joint venture between Zydus and Hospira Inc., USA (now part of Pfizer group)
  • Bayer Zydus Pharma Pvt. Ltd. -  Bayer (South East Asia) Pte. Ltd. (wholly owned subsidiary of Bayer AG, Germany) and Zydus Lifesciences Limited have a 75:25 marketing joint venture.

Zydus Lifesciences Limited - Mergers and Acquisitions

Zydus Lifesciences has raised a total of $7 million in investment. It was funded by Baring Private Equity India in a Post-IPO Equity round.

Zydus Lifesciences Limited - Mergers and Acquisitions


Till now, Zydus has purchased three businesses. Windlass Biotech was their most recent purchase as of August 13, 2018. For Rs 160 crores, they bought Windlass Biotech. Windlass Biotech is Gurgaon-based healthcare that engages in pharmaceutical drug development and contract research services. Here is the list of acquisitions made by Zydus:

Date Acquiree name Amount
August 13, 2018 Windlass Biotech Rs 160 crores
January 19, 2017 Sentynl Therapeutics, Inc. -
December 22, 2011 Biochem Pharmaceuticals -

Zydus Lifesciences Limited - Advertisements and Social Media Campaigns

Recently, Zydus Lifesciences re-launched the popular energy drink of children 'Complan' with improved taste. It was accompanied by the tagline "Ummeedo se aage badhne ka plan" campaign, which communicates the crucial advantages of the brand. The advertisement focuses that if children consume Complan it will not only improve their growth but also their memory and attention.

Zydus Lifesciences Limited - Awards and Achievements

The list of awards and achievements won by Zydus Lifesciences are;

  • Zydus received the IDMA Aptar innovation of the year award and Corporate citizen award (2022)
  • Pharma Company Of The Year Award by ETHealthworld India Pharmaworld Awards 2022
  • Zydus achieved the HR Asia award in the category of Best Companies to work in Asia 2021 in the India region.
  • Zydus was declared the most Innovative Pharmaceutical Company by Thomson Reuters.
  • Zydus received the 7th India Pharma and India Medical Device award by the Government of India (2021-2022)
  • Zydus was recognized for Excellence In CSR at ETHealthworld India Pharmaworld Awards 2022.
  • Zydus Lifesciences was recognized as India’s Best Workplace in Biotechnology and Pharmaceuticals by Great place to work 2022.

Zydus Lifesciences Limited - Competitors

The list of top competitors of Zydus Lifesciences is:

  1. Dr. Reddy's Laboratories
  2. Sun Pharmaceuticals
  3. Divi's Laboratories
  4. Cipla Limited
  5. Torrent Pharma
  6. Glenmark
  7. Abbott India
  8. Alkem Lab
  9. Aurobindo Pharma Ltd.
  10. Lupin Ltd.
  11. Ajanta Pharma
  12. Pfizer

Zydus Lifesciences Limited - Future Plans

Zydus Lifesciences Ltd. recently announced the acquisition of up to an 11.86% stake in AMP Energy Green Nine. The company is also planning to launch Lenalidomide capsules, which is a cancer treatment medication that works in slowing or preventing cancer cell proliferation in the USA market.

FAQs

Who is the CEO of Zydus?

Tarun G Arora is the CEO of Zydus.

Is Zydus a public company?

Yes, Zydus is a public company.

Where is the headquarter of Zydus Lifesciences?

The headquarter of Zydus Lifesciences is in Ahemdabad.

What is the rank of Zydus in India?

In Ind, Zydus ranks as the 4th biggest pharma company.

Must have tools for startups - Recommended by StartupTalky

Great! Next, complete checkout for full access to StartupTalky.
Welcome back! You've successfully signed in.
You've successfully subscribed to StartupTalky.
Success! Your account is fully activated, you now have access to all content.
Success! Your billing info has been updated.
Your billing was not updated.